EAACI Guidelines on Allergen Immunotherapy: IgE–mediated Food Allergy

Article in Allergy · September 2017
DOI: 10.1111/all.13319

36 authors, including:

Cezmi A Akdis
Swiss Institute of Allergy and Asthma Research
546 PUBLICATIONS 24,848 CITATIONS

Montserrat Alvaro
University of Barcelona
37 PUBLICATIONS 276 CITATIONS

Edward Knol
University Medical Center Utrecht
270 PUBLICATIONS 7,105 CITATIONS

Alexandra Santos
King's College London
76 PUBLICATIONS 1,887 CITATIONS

Some of the authors of this publication are also working on these related projects:

The epidemiology, healthcare and societal burden and costs of asthma in the UK and its member nations: Analyses of standalone and linked national databases View project

Health IT Policy View project

All content following this page was uploaded by Stefania Arasi on 02 November 2017.
The user has requested enhancement of the downloaded file.
EAACI GUIDELINES ON ALLERGEN IMMUNOTHERAPY

IgE-MEDIATED FOOD ALLERGY

AFFILIATIONS

1 Department of Pediatrics, Allergy Unit, University of Messina, Italy
2 Allergy Department, Hospital Clínico San Carlos, IdiSSC, Madrid, Spain
3 Pediatric Pneumology and Immunology, Charité Universitätsmedizin, Berlin, Germany
4 The David Hide Asthma and Allergy Research Centre, St Mary’s Hospital, Newport Isle of Wight; NIHR Southampton Biomedical Research Centre, University Hospital Southampton NHS Foundation Trust, Southampton, UK & Faculty of Medicine, University of Southampton, Southampton, UK
5 Swiss Institute for Allergy and Asthma Research; University of Zurich, Davos, Switzerland
6 Paediatric Allergy and Clinical Immunology Section, Hospital Sant Joan de Déu, Universitat de Barcelona, Barcelona, Spain
7 Charité Universitätsmedizin, Pediatric Pneumology and Immunology, Berlin, Germany & Icahn School of Medicine at Mount Sinai, New York, USA
8 Odense Research Center for anaphylaxis. Department of Dermatology and Allergy Center
9 University of North Carolina at Chapel Hill, School of Medicine, Department of Pediatrics, Chapel Hill, NC, USA
10 Department of Allergy, Clinical Research Center for Allergy & Rheumatology, Sagamihara National Hospital, Sagamihara, Kanagawa Japan
11 University Hospitals of Geneva and Medical School of the University of Geneva, Switzerland
12 Department of Immunology and Department of Dermatology & Allergology, University Medical Center Utrecht, The Netherlands
13 Department of Pediatrics, Division of Immunology, Allergy and Rheumatology, Stanford University, Stanford, California, USA
14 Allergy Clinic, Copenhagen University Hospital, Gentofte, Denmark
15 Departments of Experimental Immunology and of Otorhinolaryngology, Academic Medical Center, Amsterdam, The Netherlands
16 Department of Paediatric Allergy, Division of Asthma Allergy and Lung Biology, King’s College London; Guy’s & St Thomas’ Hospital; MRC & Asthma UK Centre in Allergic Mechanisms of Asthma, London, UK
17 Evidence-Based Health Care Ltd, Edinburgh, UK
18 Division of Population Medicine Neuadd Meirionnydd School of Medicine, Cardiff University, Heath Park, Cardiff, UK
19 EAACI Patient Organization Committee- Region de Mans- France
20 Skin and Allergy Hospital, Helsinki University Hospital, Helsinki, Finland
21 University of Athens, 2nd Pediatric Clinic, Allergy, Athens, Greece
22 Koç University Hospital, Istanbul, Turkey
23 Faculty of Medicine, Department of Allergy and Clinical Immunology, Transylvania University Brasov, Brasov, Romania.
24 Sheffield Teaching Hospital, Sheffield, UK
25 Hans Christian Andersen Children’s Hospital, Odense University Hospital, Odense, Denmark
26 Wroclaw Medical University, Wroclaw, Poland
27 ALL-MED Medical Research Institute, Wroclaw, Poland
28 Department of Otorhinolaryngology, Head and Neck Surgery, Universitätsmedizin Mannheim, Medical Faculty Mannheim, Heidelberg University, Mannheim, Germany
29 Center for Rhinology and Allergology, Wiesbaden, Germany
30 Allergy and Respiratory Research Group, Usher Institute of Population Health Sciences and Informatics, University of Edinburgh, Medical School, Edinburgh, UK
31 I Department of Dermatology and Venerology, Medical University of Graz, Graz, Austria; Outpatient Allergy Clinic Reumannplaz, Vienna, Austria
32 Department of Paediatric and Adolescent Medicine, Respiratory and Allergic Disease Division, Medical University of Graz, Austria
33 Section of Allergology, Department of Internal Medicine, Erasmus Medical Center, Rotterdam, The Netherlands
34 Food Allergy Referral Centre, Veneto Region Department of Women and Child Health, Padua General University Hospital, Padua, Italy

* Denotes equal contribution
Food allergy can result in considerable morbidity, impairment of quality of life and healthcare expenditure. There is therefore interest in novel strategies for its treatment, particularly food allergy allergen immunotherapy (FA-AIT) through the oral (OIT), sublingual (SLIT) or epicutaneous (EPIT) routes. This Guideline, prepared by the European Academy of Allergy and Clinical Immunology (EAACI) Task Force on Allergen Immunotherapy for IgE-mediated Food Allergy, aims to provide evidence-based recommendations for active treatment of IgE-mediated food allergy with FA-AIT. Immunotherapy relies on the delivery of gradually increasing doses of specific allergen to increase the threshold of reaction while on therapy (also known as desensitization) and ultimately to achieve post-discontinuation effectiveness (also known as tolerance or sustained unresponsiveness). Oral AIT has most frequently been assessed: here the allergen is either immediately swallowed (OIT) or held under the tongue for a period of time (SLIT). Overall, trials have found substantial benefit for patients undergoing either OIT or SLIT with respect to efficacy during treatment, particularly for cow’s milk, hen’s egg and peanut allergies. A benefit post-discontinuation is also suggested, but not confirmed. Adverse events during AIT have been frequently reported, but few subjects discontinue FA-AIT as a result of these. Taking into account the current evidence, AIT should only be performed in research centers or in clinical centers with an extensive experience in food allergy AIT. Patients and their families should be provided with information about the use of AIT for IgE-mediated food allergy to allow them to make an informed decision about the therapy.

INTRODUCTION

Food allergy (FA) has emerged as a significant medical problem in recent decades. With FA now affecting up to 8% of children and 5% of adults in westernised countries, development of therapies for this potentially life-threatening condition has become a public health priority (1-3). The key terms and clinical presentation of FA are summarised in Boxes 1 and 2. The current approach in managing FA focuses on avoidance of trigger foods and the availability of and training in the use of rescue medication in the event of an allergic reaction. Allergen immunotherapy (AIT) is potentially a curative therapy. AIT may increase the amount of food that the patient can tolerate, preventing allergic symptoms and reducing the risk of potentially life-threatening allergic reactions. The first case of immunotherapy for food allergy (FA-AIT) was described in 1908 to hen’s egg (HE) (4); the principles underlying the therapy have remained the same, i.e. therapy consists of the administration of gradually increasing doses of food allergens via the oral, sublingual or subcutaneous routes (2). A fixed dose of allergen can be administered through the epicutaneous route (2).

The ultimate goal of FA-AIT is to achieve post-discontinuation effectiveness so that a patient can eat a normal serving of the trigger food without symptoms. This is also known as “tolerance” or “sustained unresponsiveness”. These terms all imply that the food allergen can be ingested without the appearance of allergic symptoms despite a period of absence of exposure. The time period required to establish true post-discontinuation effectiveness is not yet defined. Based on current evidence, a more attainable target is effectiveness during treatment (typically referred to as “desensitisation”) which refers to a reversible or partially reversible clinical response that is dependent on ongoing allergen exposure. If the administration of the allergen is discontinued, the previous level of clinical reactivity may return (5).

The primary outcome of FA-AIT is a change in the threshold of allergen required to trigger an allergic reaction determined by an oral food challenge (OFC) - where possible, this is preferably a double-blind.

**Box 1  Key terms**

<table>
<thead>
<tr>
<th>Allergen immunotherapy</th>
<th>Repeated allergen exposure at regular intervals to modulate immune response to reduce symptoms and the need for medication for clinical allergies and to prevent the development of new allergies. This is also known as allergen specific immunotherapy.</th>
</tr>
</thead>
<tbody>
<tr>
<td>Effectiveness during treatment</td>
<td>The ability to safely consume foods containing the culprit allergen while on allergen immunotherapy. This clinical response is dependent on ongoing allergen exposure. If the administration of the allergen is discontinued, the previous level of clinical reactivity may return. This is also referred to as “desensitization”.</td>
</tr>
<tr>
<td>Food</td>
<td>Any substance, whether processed, semi-processed, or raw, which is intended for human consumption, and includes drink, chewing gum, and any substance which has been used in the manufacture, preparation, or treatment of ‘food’ but does not include cosmetics or tobacco or substances used only as drugs [Codex Alimentarius]. Food is eaten, drunk or otherwise taken to the body to provide energy and nutritional support, maintain life, or stimulate growth.</td>
</tr>
<tr>
<td>Food allergy</td>
<td>An adverse reaction to food mediated by an immunologic mechanism, involving specific-IgE (IgE-mediated), cell-mediated mechanisms (non-IgE-mediated) or both IgE- and cell-mediated mechanisms (mixed IgE- and non-IgE-mediated) [from EAACI Food Allergy and Anaphylaxis Guidelines (3)].</td>
</tr>
<tr>
<td>Post-discontinuation effectiveness</td>
<td>The ability to safely consume a normal serving of food containing the trigger allergen despite a period of absence of exposure. This is also known as “tolerance” or “sustained unresponsiveness”.</td>
</tr>
<tr>
<td>Sensitization</td>
<td>Detectable IgE antibodies, either by means of skin prick test or determination of serum specific-IgE antibodies.</td>
</tr>
</tbody>
</table>
Box 2 Clinical presentations of IgE-mediated food allergy

<table>
<thead>
<tr>
<th>Systems</th>
<th>Symptoms</th>
</tr>
</thead>
<tbody>
<tr>
<td>Cutaneous</td>
<td>pruritus, erythema/flushing, urticaria, angioedema, contact urticaria</td>
</tr>
<tr>
<td>Ocular</td>
<td>itching, redness, tearing, periorbital edema</td>
</tr>
<tr>
<td>Oropharynx</td>
<td>itching, dryness/discomfort, swelling of the oral cavity, lips, tongue and/or pharynx</td>
</tr>
<tr>
<td>Respiratory tract</td>
<td>nasal congestion, nasal pruritus, rhinorrhea, sneezing hoarseness, laryngeal edema, dysphonia, shortness of breath, cough, wheezing, chest tightness/pain</td>
</tr>
<tr>
<td>Gastrointestinal</td>
<td>abdominal pain, nausea, emesis, diarrhea</td>
</tr>
<tr>
<td>Cardiovascular/Neurological</td>
<td>tachycardia, hypotension, dizziness, loss of consciousness/fainting, seizures, incontinence</td>
</tr>
<tr>
<td>Multi-organ</td>
<td>anaphylaxis</td>
</tr>
<tr>
<td>Miscellaneous</td>
<td>sense of impending doom, uterine cramping/contractions</td>
</tr>
</tbody>
</table>

placebo-controlled, food challenge (DBPCFC). There is great variability in the threshold of exposure between different studies and for different foods (6, 7). Additional parameters have been studied in the monitoring of FA-AIT, including: skin prick tests (SPT) (8), specific-IgE (sIgE), IgG and IgG4 levels in serum (9). Some studies have also looked at basophil activation tests (BAT) (10), cytokines (e.g. IL-10, IL-5 and IFN-γ) (11,12), and regulatory T-cells (13).

The most frequent route of administration of FA-AIT is the oral route where the allergen is either immediately swallowed (oral immunotherapy, OIT) or held under the tongue for a period of time (sublingual immunotherapy, SLIT). There are currently ongoing studies using the subcutaneous route (subcutaneous immunotherapy, SCIT) for peanut and fish allergies (14-16). Epicutaneous immunotherapy (EPIT) is also under investigation for peanut and cow’s milk (CM); it involves application of patches containing food allergen onto the skin (17). In general, there has been no consistent formulation of food in FA-AIT studies conducted to date (18). Dilutions of unprocessed products, crude extracts and flours have been used. Some studies have been carried out with powdered or lyophilized products. Only a few have used food extracts with a quantification of major allergens prepared by pharmaceutical companies or hospital pharmacies (11, 19).

This Guideline has been prepared by the European Academy of Allergy and Clinical Immunology (EAACI) Task Force on Allergen Immunotherapy for IgE-mediated Food Allergy. It is part of the EAACI Guidelines on Allergen Immunotherapy. This Guideline aims to provide evidence-based recommendations for the use of AIT in patients with diagnosed IgE-mediated FA. The primary audience are clinical allergists. This Guideline is also likely to be of relevance to other healthcare professionals (e.g. other doctors, nurses, dieticians, psychologists and paramedics) who are involved in the management of patients with food allergy and their families in any setting.

The development of this Guideline has been informed by a formal systematic review (SR) and meta-analysis on FA-AIT that included 31 trials studying 1259 patients. There were 25 randomised clinical trials (RCT) and 6 non-randomised controlled clinical trials (CCT). OIT was covered by 25 studies, SLIT was used in 5, and EPIT in 1. The food allergies most frequently studied were CM (16 studies), HE (11 studies), and peanut (7 studies) (18).

**METHODOLOGY**

This Guideline was produced using the Appraisal of Guidelines for Research & Evaluation (AGREE II) framework (20, 21), which is a structured approach to guideline production. This is designed to ensure appropriate representation of the full range of stakeholders, a careful search for and critical appraisal of the relevant literature, a systematic approach to the formulation and presentation of recommendations, and steps to ensure that the risk of bias is minimised.
at each step of the process. The process started in April 2015 beginning with detailed face-to-face discussions agreeing on the process and the key clinical areas to address, followed by face-to-face meetings and web-conferences in which professional and lay representatives participated.

Clarifying the scope and purpose of the Guidelines
This Guideline aims to assist qualified clinicians in the optimal use of AIT in the management of patients with IgE-mediated FA, and highlight gaps for further research.

Ensuring appropriate stakeholder involvement
Participants in the EAACI Taskforce on FA-AIT represented a range of 16 countries, and different disciplinary and clinical backgrounds, including allergists, paediatricians, primary care physicians, immunologists and patient group representatives. Additionally, producers of AIT products were given the opportunity to review and comment on the draft Guideline.

Systematic review of the evidence
The initial full range of questions that were considered important were rationalized through several rounds of iteration to agree one key question: what is the effectiveness, changes in disease-specific quality of life (QoL), cost-effectiveness and safety of AIT in patients with IgE-mediated FA. This was then pursued through a formal SR of the evidence by independent methodologists as previously published (18) (Box 3). We continued to track evidence published after our SR cut-off date of 31st March 2016 and, where relevant, recent studies were considered by the Taskforce’s joint Chairs. This most recent evidence will formally be considered in the SR update that will precede the update of this Guideline.

Formulating recommendations
We assessed the strength, consistency and quality of evidence in relation to key findings from the SR and meta-analyses (18) (which were undertaken using random-effects models to take into account the heterogeneity of findings) to formulate evidence-based recommendations for clinical care (Box 4) (22). This involved formulating clear recommendations with the strength of evidence underpinning each recommendation. Where the SR did not cover the clinical area, we took a hierarchical approach reviewing other evidence until we could formulate a recommendation, i.e. (i) other SRs on the subject to see if these provided any clarity on the topic; (ii) RCTs within these systematic reviews; (iii) other RCTs known to Taskforce members; and (iv) an expert consensus-based approach. This evidence was also assessed, as described above. Experts identified the resource implications of implementing the recommendations, barriers, and facilitators to the implementation of each recommendation, advice on approaches to implementing the recommendations and suggested audit criteria that can help with assessing organisational compliance with each recommendation.

Box 3 Summary of the aims and outcomes of the supporting systematic review (18)

<table>
<thead>
<tr>
<th>Aim</th>
<th>Outcomes of the SR:</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Aim</strong></td>
<td>To provide a systematic review of the evidence on the effectiveness, safety and cost-effectiveness of AIT for IgE-mediated food allergy.</td>
</tr>
<tr>
<td><strong>Primary</strong></td>
<td>• Effectiveness during the treatment (i.e. the ability to safely consume foods containing the allergen in question while on AIT) or post-discontinuation effectiveness (the ability to consume foods containing the allergen in question after discontinuing AIT) at food challenge.</td>
</tr>
<tr>
<td></td>
<td>• Assessment of changes in disease specific quality of life (QoL) using a validated instrument.</td>
</tr>
<tr>
<td><strong>Secondary</strong></td>
<td>• Secondary outcome measures of interest were safety as assessed by local and systemic reactions in accordance with the WAO grading system of side-effects</td>
</tr>
<tr>
<td></td>
<td>• Health economic analysis from the perspective of the health system/payer as reported in studies.</td>
</tr>
</tbody>
</table>
Box 4 Assigning levels of evidence and recommendations

<table>
<thead>
<tr>
<th>LEVEL OF EVIDENCE</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>Level I</td>
<td>Systematic reviews, meta-analysis, randomized controlled trials</td>
</tr>
<tr>
<td>Level II</td>
<td>Two groups, non-randomized studies (e.g., cohort, case-control)</td>
</tr>
<tr>
<td>Level III</td>
<td>One group non-randomized (e.g., before and after, pre-test, and post-test)</td>
</tr>
<tr>
<td>Level IV</td>
<td>Descriptive studies that include analysis of outcomes (single-subject design, case series)</td>
</tr>
<tr>
<td>Level V</td>
<td>Case reports and expert opinion that include narrative literature, reviews, and consensus statements</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>GRADES OF RECOMMENDATION</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>Grade A</td>
<td>Consistent level I studies</td>
</tr>
<tr>
<td>Grade B</td>
<td>Consistent level II or III studies or extrapolations from level I studies</td>
</tr>
<tr>
<td>Grade C</td>
<td>Level IV studies or extrapolations from level II or III studies</td>
</tr>
<tr>
<td>Grade D</td>
<td>Level V evidence or troublingly inconsistent or inconclusive studies at any level</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>STRENGTH OF RECOMMENDATIONS</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>Strong</td>
<td>Evidence from studies at low risk of bias</td>
</tr>
<tr>
<td>Moderate</td>
<td>Evidence from studies at moderate risk of bias</td>
</tr>
<tr>
<td>Weak</td>
<td>Evidence from studies at high risk of bias</td>
</tr>
</tbody>
</table>

Recommendations are phrased according to the strength of recommendation: strong, “is recommended”; moderate, “can be recommended”; weak, “may be recommended in specific circumstances”; negative, “cannot be recommended”.

Approach adapted from Oxford Centre for Evidence-based Medicine - Levels of Evidence and Grades of Recommendations (22). The adaptation involved providing an assessment of the risk of bias, based on the Cochrane risk of bias tool, of the underpinning evidence and highlighting other potentially relevant contextual information.

Peer review and public comment
A draft of this Guideline was externally peer-reviewed by invited external experts from a range of organisations, countries, and professional backgrounds. Additionally, the draft Guideline was made available on the EAACI Website for a 3-week period in May 2017 to allow a broader array of stakeholders to comment. All feedback was considered by the Taskforce and, where appropriate, final revisions were made in light of the feedback received. We will be pleased to continue to receive feedback on this Guideline, which should be addressed to the corresponding author.

Identification of evidence gaps
The process of developing this Guideline has identified a number of evidence gaps which we have prioritised.

Editorial independence and managing conflict of interests
The production of this Guideline was funded and supported by EAACI. The funder did not have any influence on the guideline production process, on its contents, or on the decision to publish. Taskforce members’ conflict of interests were taken into account by the Taskforce Chairs as recommendations were formulated. Final decisions about strength of evidence for recommendations were reviewed by methodologists who had no conflict of interests in this area.

Updating the guidelines
We plan to update this Guideline in 2021 unless there are important advances before then.
GENERAL CONSIDERATIONS BEFORE INITIATING AIT FOR IgE-MEDIATED FOOD ALLERGY

AIT is potentially indicated for patients with evidence of an IgE-mediated FA and in whom avoidance measures are ineffective, undesirable or cause severe limitations to a patient’s QoL. Prior to initiating AIT, confirming the diagnosis of IgE-mediated FA is mandatory. This requires a recent, clear clinical history of an acute reaction(s) after consumption of the triggering food. The presence of IgE to the triggering food should be established with SPT and/or sIgE. Where the diagnosis is unclear, an OFC is required. The baseline reaction threshold may be used to establish the efficacy of AIT in individual patients (Box 5).

Studies to date have enrolled patients with heterogeneous ages and clinical presentations (18). Studies have included infants and pre-school children who have tolerated FA-AIT safely (23, 24). However, the limited ability of young children to report early symptoms of allergic reactions should be considered. Furthermore, young children have a high likelihood of developing spontaneous tolerance, particularly to CM, HE, wheat and soy (25-31). Therefore, it might be more appropriate to wait for the natural acquisition of spontaneous tolerance before commencing AIT for these allergens (25-31). The right time to start may be around 4-5 years of age, but this should be decided on an individual basis.

FA-AIT is logistically demanding, time-consuming and most patients are affected by side effects. These are usually mild, but systemic reactions - including life-threatening anaphylaxis - may occur. AIT for FA should therefore only be undertaken in centres with professional training in FA care with the expertise, competencies and full resuscitation facilities to safely deliver this therapy and manage any complications, including anaphylaxis (Box 6). Only patients and families who understand the aim of the intervention and its risks, and are motivated and adherent should be considered for FA-AIT (Boxes S1 and S2 in the online). There are therefore many issues to be considered and discussed with the patient and family before commencing FA AIT (Box 7).

Box 5  Diagnosis of IgE-mediated food allergy before initiating FA-AIT

- Detailed medical history to establish current clinical reactivity to the food (recent reactions)
- Allergy testing (skin prick tests-SPTs, with food allergen extracts or fresh foods) and/or specific IgE (sIgE) to food allergen extract(s) or component(s) (component resolved diagnosis, CRD)
- Oral food challenge (OFC)

Box 6  Personnel and equipment required to perform FA-AIT

**Personnel**  Medical doctor and nurse trained and experienced in the diagnosis of food allergy including oral challenges, and trained and experienced in the recognition and treatment of allergic reactions including anaphylaxis. Personnel should be able to provide at least 12 hours of observation in case of adverse reactions related to AIT.

#Anesthesiology team or intensive care or equivalent team particularly trained in resuscitation on call, at hand within 5 minutes.

**Equipment**  Stethoscope
Sphygmomanometer
Pulse oximeter
Oxygen
Spirometer, peak flow meter
Laryngoscope(s), intubation tube(s), ventilation bag(s)
Heart defibrillator (knowledge and experience how to use it)
#Crash trolley

**Medication**  Adrenaline (epinephrine), antihistamine (oral and parenteral), inhaled beta2-agonist, corticosteroids (oral, parenteral).
IV lines and IV fluids

# According to the local facilities and organization of assistance to patients experiencing severe anaphylaxis.
GENERAL CONTRAINDICATIONS

Given the long-treatment duration and common adverse reactions, any medical or social condition that might prevent patients attending frequent clinical visits, being aware of side effects or adhering to treatment represents an absolute contraindication. Uncontrolled asthma is also an absolute contraindication as it is associated with an increased risk of life-threatening systemic reactions (32). Well-controlled asthma is however not a contraindication for FA-AIT. Although a history of moderate to severe anaphylaxis to a food may be associated with more side effects, it is not a contraindication; these patients require appropriate evaluation before starting FA-AIT and close supervision particularly during the build-up phase. Uncontrolled, severe atopic dermatitis/eczema and chronic urticaria are relative contraindications given the risk of acute exacerbation while on AIT and because they can confound safety assessment of AIT. Therefore, both disorders should be controlled before AIT is initiated. The presence of eosinophilic esophagitis (EoE) or any other eosinophilic gastrointestinal disease is a contraindication for FA-AIT because of the risk these worsen whilst on FA-AIT (33, 34).

There is a lack of available data on the risks associated with FA-AIT in autoimmune disorders, severe medical conditions such as cardiovascular diseases, mastocytosis, or with the concomitant use of medications such as beta-blockers or angiotensin-converting enzyme (ACE) inhibitors. However, the risk in other types of AIT has been assessed (35-39): these conditions can be considered relative contraindications, and FA-AIT should only be used with caution when likely benefits outweigh risks (Box 8). The final decision about starting AIT should be established on an individual basis in discussion with the patient and/or family.

EFFECTIVENESS OF DIFFERENT APPROACHES TO AIT FOR IgE-MEDIATED FOOD ALLERGY

The effectiveness of FA-AIT has to be assessed in relation to the culprit food and route of administration.

Effectiveness of oral immunotherapy

A recently performed SR identified 23 trials: 18 RCTs and 5 CCTs (18). A meta-analysis of 22 of these trials involving 982 subjects revealed a substantial benefit for the patients (children and mixed population) undergoing OIT with CM, HE and peanut with respect to efficacy during treatment (RR 0.14, 95% CI 0.08, 0.24) (18).
There were 7 studies included in the SR (18) that assessed post-discontinuation effectiveness, but only 4 studies could be included in the meta-analysis (8, 40-42). This analysis suggested but did not confirm the longer-term benefits of OIT (RR 0.29, 95% CI 0.08, 1.13) (18). These 4 trials covered HE (8, 40-42) (169 subjects) and CM (40) (25 subjects), and assessed effectiveness by an oral challenge performed after 1 to 3 months of discontinuation of OIT. No subgroup analysis on the type of food or period of discontinuation could be performed. In an egg OIT trial, published after our SR (43), post-discontinuation effectiveness of egg OIT was enhanced with duration of OIT; however, there was no control group in the follow-up period to compare with natural resolution of the egg allergy. In this trial children were treated for up to 4 years, whereas those included in the meta-analysis were treated for a shorter period of time.

Regimens for OIT varied widely from rush protocols to slow up-dosing regimens with or without an initial dose escalation day (18). There was no apparent difference regarding effectiveness during treatment between CM, HE and peanut, and between the different protocols with all showing substantial effectiveness during treatment (18). The data published to date do not allow the ideal treatment regimen, including doses and intervals, to be determined. Additionally, the definition of effectiveness (i.e. increment of threshold) and its assessment varied among studies, and so the overall magnitude of the effect cannot be established.

In conclusion, FA-OIT is recommended for persistent CM, HE or peanut allergy for children from around 4 to 5 years of age on the basis of its ability to increase the threshold for clinical reactions while on OIT (Grade A) (Table 1-3). At present, there are insufficient data to be able to recommend AIT for other foods (Table 4) and for adults outside clinical trials (Table 5).

Effectiveness of sublingual immunotherapy

There are few published studies which have assessed the effectiveness of SLIT. A recent meta-analysis identified four placebo-controlled RCTs and one CCT for the assessment of efficacy of SLIT while on therapy (18). The total number of patients treated was limited (n=189), and the food allergies covered included peanut (12, 52), hazelnut (11), and peach (53) in RCTs, and different foods in a CCT (50) (RR=0.26, 95% CI 0.10, 0.64). Overall, SLIT revealed substantial benefits for the patients in regard to desensitization (18),

<table>
<thead>
<tr>
<th>Evidence Grade of recommendation level</th>
<th>Strength of recommendation</th>
<th>Grade of recommendation</th>
<th>Recommendation</th>
</tr>
</thead>
<tbody>
<tr>
<td>I</td>
<td>A</td>
<td>Strong recommendation based on convincing evidence from SR and meta-analysis.</td>
<td>OIT is recommended as a treatment option to increase threshold of reaction while on treatment in children with persistent CM allergy from around 4 - 5 years of age.</td>
</tr>
<tr>
<td>7, 9, low risk of bias (4)</td>
<td>I</td>
<td>Age recommendation is based on expert opinion.</td>
<td>A recommendation cannot currently be made for OIT as a treatment option in children with persistent CM allergy with the goal of post discontinuation effectiveness.</td>
</tr>
</tbody>
</table>

*OIT for food allergy should only be undertaken in highly specialised clinical centres with expertise and facilities to safely deliver this therapy.

Table 1 Recommendations on efficacy of OIT in children with persistent cow’s milk allergy

58 EAACI
**Table 2** Recommendations on efficacy of OIT in children with hen’s egg allergy

<table>
<thead>
<tr>
<th>Recommendations*</th>
<th>Evidence level</th>
<th>Grade of recommendation</th>
<th>Strength of recommendation</th>
<th>Other considerations</th>
<th>Key references</th>
</tr>
</thead>
<tbody>
<tr>
<td>OIT can be recommended as a treatment option to increase the threshold of reaction while on OIT in children with persistent hen’s egg allergy, from around 4 - 5 years of age.</td>
<td>I</td>
<td>B</td>
<td>Moderate recommendation based on evidence for effect from SR and meta-analysis (18) including low risk of bias RCTs (8, 42). Studies are all small with some heterogeneity in results.</td>
<td>Risk of adverse reactions needs to be considered. Age recommendation is based on expert opinion. Additional large studies required.</td>
<td>Nurmatov, 2017 (18); Burks, 2012 (8); Caminiti 2015 (42)</td>
</tr>
<tr>
<td>A recommendation cannot currently be made for OIT as a treatment option to achieve post-discontinuation effectiveness in children with persistent hen’s egg allergy</td>
<td>I</td>
<td>B</td>
<td>Strong recommendation based on only one RCT with low risk of bias (43)</td>
<td>After 4 years of OIT 50% of subjects achieved sustained unresponsiveness 4-6 weeks after stopping OIT (43). Further studies needed.</td>
<td>Jones 2016 (43)</td>
</tr>
</tbody>
</table>

* OIT for food allergy should only be undertaken in highly specialised clinical centres with expertise and facilities to safely deliver this therapy.

**Table 3** Recommendations on efficacy of OIT in children with persistent peanut allergy

<table>
<thead>
<tr>
<th>Recommendations*</th>
<th>Evidence level</th>
<th>Grade of recommendation</th>
<th>Strength of recommendation</th>
<th>Other considerations</th>
<th>Key references</th>
</tr>
</thead>
<tbody>
<tr>
<td>OIT is recommended as a treatment option to increase the threshold of reaction while on treatment in children with peanut allergy from around 4-5 years of age.</td>
<td>I</td>
<td>A</td>
<td>Strong recommendation based on consistent evidence from SR and meta-analysis (18) with low risk of bias RCTs (45-47)</td>
<td>Risk of adverse reactions to be considered. Age recommendation is based on expert opinion.</td>
<td>Nurmatov 2017 (18); Narisety 2015 (45); Tang, 2015 (46); Varshney 2011 (47)</td>
</tr>
<tr>
<td>A recommendation cannot currently be made for OIT as a treatment option to achieve post discontinuation effectiveness in children with peanut allergy</td>
<td>I</td>
<td>B</td>
<td>Strong recommendation based on two RCTs at low risk of bias (23, 45)</td>
<td>Inconsistent study results. Further studies needed.</td>
<td>Vickery 2017 (23), Narisety 2014 (45)</td>
</tr>
</tbody>
</table>

* OIT for food allergy should only be undertaken in highly specialised clinical centres with expertise and facilities to safely deliver this therapy.

**Table 4** Recommendations on efficacy of OIT in children with persistent allergies to other foods

<table>
<thead>
<tr>
<th>Recommendations*</th>
<th>Evidence level</th>
<th>Grade of recommendation</th>
<th>Strength of recommendation</th>
<th>Other considerations</th>
<th>Key references</th>
</tr>
</thead>
<tbody>
<tr>
<td>A recommendation cannot currently be made for OIT as a treatment option to increase the threshold of reaction while on treatment in children allergic to other foods (e.g. fish, wheat, peach)</td>
<td>II</td>
<td>B</td>
<td>Weak recommendation based on a few cases reported in one RCT at high risk of bias (48) and two CCTs at moderate risk of bias (49, 50)</td>
<td>Risk of adverse reactions to be considered</td>
<td>Patriarca, 1998 (48); Patriarca, 2003 (49); Patriarca, 2007 (50)</td>
</tr>
</tbody>
</table>

* OIT for food allergy should only be undertaken in highly specialised clinical centres with expertise and facilities to safely deliver this therapy.
but none of the studies included in the SR assessed post-discontinuation effectiveness. However, an open follow-up of a peanut SLIT trial in children and adults found only 11% of patients achieving tolerance after three years on SLIT and post-discontinuation of the AIT for 4-6 weeks (54).

**Head-to-head trials of OIT versus SLIT**

Two trials directly compared the efficacy of OIT and SLIT: the first focused on CM (55) and the second on peanut allergy (45). The first trial randomized 30 children with CM allergy to SLIT alone or SLIT followed by OIT. This trial clearly showed that OIT after SLIT was more efficacious for desensitization and sustained unresponsiveness after six weeks off therapy to CM than SLIT alone (55). The second trial was a double-blind study involving 21 children with peanut allergy who were randomized to receive either active SLIT/placebo OIT or active OIT/placebo SLIT. As in the CM trial, OIT was far more effective than SLIT for the treatment of peanut allergy as the increased threshold was significantly greater in the active OIT group while on therapy (45). OIT would seem to be a better therapeutic option than SLIT, but it is associated with significantly more adverse reactions. Currently, we cannot recommend SLIT for FA due to the limited effectiveness.

**Other routes of AIT under investigation**

EPIT with unmodified allergens is currently under investigation for peanut and CM. Efficacy results of one placebo controlled RCT with peanut EPIT in 74 subjects aged 4-25 years have shown an increase in the threshold of reaction while on therapy. This effect was higher in patients younger than 11 years of age (17). Moreover, SCIT with modified allergens is also under development (14-16). Two SCIT trials are currently ongoing: one using a chemically modified peanut extract (14) and another one using hypoallergenic recombinant parvalbumin for fish allergy (16). And finally, a phase 1 trial with modified peanut allergens administered by the rectal route has been conducted, but showed significant side effects, which led to early termination of the trial (56). At present, we cannot recommend EPIT or SCIT for FA-AIT.
SAFETY OF AIT

Alongside efficacy, safety is pivotal to any treatment. In AIT, safety is particularly important, as potential adverse events are mostly immediate onset, food-induced IgE-mediated reactions, which can lead to anaphylaxis. Events related to safety have been highlighted in the studies addressed by the SR (18). The heterogeneity in the reporting formats reduced the number of studies that could be pooled in the meta-analysis. Despite this, it was shown that patients receiving the active preparation experienced significantly more reactions, both systemic and local, than those who received placebo (18). Recommendations on safety of AIT are shown in Table 6.

Oral immunotherapy

OIT to foods is associated with a large number of local reactions. These are mainly itching of the oropharynx, perioral rash, and mild abdominal pain and can be bothersome when they occur repeatedly. Local reactions may evolve into more severe systemic reactions, but only a minority of patients experiences these. Results for systemic reactions from five OIT studies and for local reactions from 7 studies were pooled in the meta-analysis. Patients receiving active treatment had a higher risk of systemic reactions than those in the placebo group (RR of not experiencing a systemic reaction in controls: 1.16, 95% CI 1.03, 1.30) (18). OIT was also associated with a higher risk of local reactions (RR of not experiencing a local reaction in controls: 2.14, 95% CI 1.47, 3.12) (18). No deaths have been reported in the meta-analysis (18). It is therefore recommended that patients are carefully monitored for local and systemic allergic reactions in FA-AIT, particularly during the up-dosing phase of FA-OIT (Grade A).

Dosing with an empty stomach, irregular intake, exercise, infection, medication use, menses, and suboptimal control of asthma or of allergic rhinitis may increase the risk of reactions (59-63) especially during the maintenance phase(s) of OIT, when patients continue treatment at home. Although adverse reactions have been reported in the absence of these co-factors, patients should be informed and instructed on how to manage AIT in these situations (Boxes 9 and 10). It is recommended that a careful evaluation and explanation to the patient and his/her caregiver(s) of the risk of reactions during FA-AIT is undertaken before starting AIT (Grade C) (Table 6).
Additionally, a careful evaluation of levels of sIgE, SPT and concomitant asthma control is recommended before starting FA-AIT as high levels of sIgE and skin reactivity, and asthma have been found as risk factors for adverse events (Grade B) (Table 6).

Dose adaptations are made according to the severity of allergic reactions. In mild reactions, doses can remain the same according to the protocol. With repeated mild reactions, particularly when bothersome to the patient, dose increments may be stopped, or doses may even be reduced. With systemic reactions, doses are usually reduced, although it is not established if a reduction is necessary in all patients, particularly when reactions only develop in the presence of co-factors. In patients with systemic reactions, individualized schedules with a longer and slower up-dosing phase, and premedication (antihistamines, or omalizumab) may be considered (58). We suggest a case-by-case evaluation of dose adaptation, and a thorough review of any underlying condition. The control of any concomitant allergic disease, and especially asthma, has to be optimal. Safety should remain the priority.

**Sublingual immunotherapy**

SLIT is associated with a lower risk of significant adverse events than OIT. In RCTs of SLIT (11, 12, 52-54), systemic reactions have been uncommon (<0.5-2.3% of doses) and generally mild, and appeared not to differ from those observed in the placebo treated patients. Meta-analysis of 2 SLIT studies (11, 53) did not show a significantly higher risk of systemic reactions in the active group (RR of not experiencing a systemic reaction in controls: 0.98, 95% CI 0.85, 1.14) (18). The most common adverse events in SLIT trials were mild local reactions in the oropharynx (7-40% of patients), which can be observed during both the up-dosing and maintenance phases. A meta-analysis of local reactions with SLIT could not be undertaken due to different formats in reporting reactions between trials.

**SCIT and EPIT**

The experience with SCIT using whole peanut aqueous allergen extracts is limited, mostly due to the high number of severe adverse events (including severe anaphylaxis) (64, 65). SCIT studies are currently underway with hypoallergenic recombinant parvalbumin and chemically modified peanut extract. These modified allergens have reduced allergenicity, but their safety profiles have not been yet reported (14-16).

One phase II RCT of EPIT with peanut suggests a favorable safety profile (17). Although patch-site reactions were observed in more than 90% of active treated patients, most were mild. Non-patch-site reactions were observed in less than 20% of patients, were also mild and responded to oral antihistamines or topical corticosteroids. No reactions required adrenaline.
The clinical setting for food allergy AIT
FA-AIT should only be undertaken in a setting where the full spectrum of food allergy reactions - including life-threatening anaphylaxis - can be managed (Boxes 6 and table 6). In particular, administration of initial doses and regular increments requires the presence of staff trained to manage anaphylaxis. Doses tolerated in the clinical setting are subsequently taken at home. Patients need clear instructions on how to detect an allergic reaction and its appropriate self-management. They also need to have on-hand appropriate medications including adrenaline auto-injectors. All dose increments have to be performed in a clinically specialized setting, and if no reactions are observed the same dose can be subsequently taken at home.

When to stop AIT after adverse reactions?
With repeated local adverse reactions and/or systemic adverse events, discontinuation of AIT should be discussed with the patient and/or family.

Long-term safety
Long-term safety is not addressed in trials; these predominantly focus on efficacy and short term safety. The development of EoE after OIT has been reported (33, 34, 62, 66). In a SR, new onset EoE was found in 2.7% (95% CI 1.7, 4.0). All the studies analyzed were retrospective with significant publication bias suggested by funnel plot analysis (33). It is therefore recommended to monitor patients for symptoms of new onset EoE which may appear in the course of FA-OIT (Grade A).

ALLERGEN FACTORS THAT AFFECT THE EFFECTIVENESS AND SAFETY OF AIT
In the SR on FA-AIT, the majority of trials were on CM (n=16), HE (n=11) and peanut (n=7), with only 1-3 studies for each of the other foods (18). AIT for CM, HE and peanut had similar efficacies in terms of desensitization with RR of 0.12 (95% CI 0.06, 0.25), 0.22 (0.11, 0.45) and 0.11 (0.04, 0.31), respectively. Of note, in these pooled analyses, the majority of studies were OIT with just a few SLIT ones and the products differed (e.g. peanut flour for OIT versus a peanut extract for SLIT).

Seven trials on different foods (3 CM, 1 HE, 1 peanut, 1 peach and 1 hazelnut; the latter two dealing with SLIT, and the remaining 5 with OIT) could be pooled for analysis regarding occurrence of systemic reactions. An increased risk of systemic reactions was observed with OIT, but a comparative subgroup analysis on the type of allergen could not be undertaken (18). For local reactions, milk seems more prone to cause side effects than egg although no statistically significant differences were found between them (milk 2.70, 1.33, 5.47; egg 1.55, 1.09, 2.22) (18). In conclusion, there is no evidence that the efficacy and safety are affected by the type and nature of the food allergen used in AIT.

PATIENT FACTORS THAT AFFECT THE EFFICACY AND SAFETY OF AIT
Different patient factors have been suspected to affect the outcomes of FA-AIT, both in terms of efficacy and safety. Concerning patient age, the SR and meta-analysis found that FA-AIT is effective in reducing FA in children and a population of mixed ages with IgE-mediated FA to a range of foods. It is still unclear if AIT is effective for adults. There are no studies of OIT performed exclusively in adults and in those performed with mixed (i.e. children and adult) populations, efficacy could not be analyzed separately according to age (18). The only studies focused on adults used SLIT with hazelnut and peach, and showed an increase in threshold of reaction while on therapy (11, 53).

In the SR and meta-analysis on FA-AIT, there were insufficient data to analyze the role of other patient factors such as the number of culprit foods of clinical relevance, co-existence of asthma or other severe allergic disorders, on FA-AIT outcomes (18). Some studies have shown that patients with greater IgE-sensitisation, lower threshold/higher severity and associated asthma are those with a higher frequency of adverse events (57, 58, 62). In a similar vein, some studies found that smaller SPT wheal size and lower sIgE levels have been associated with an increased likelihood of achieving desensitization and tolerance (67, 68). However, other studies did not find a significant correlation between pre-FA-AIT SPT/ sIgE
results and treatment success (45, 52), and some FA-AIT studies have included children with severe FAs or anaphylaxis with elevated sIgE who were successfully treated with FA-AIT (7, 9). Two studies performed in children allergic to CM have shown that IgE recognition of peptides of CM proteins are biomarkers that predict safety and efficacy of CM-AIT (54, 61).

ADHERENCE TO AIT
Adherence to treatment is a crucial consideration both to ensure efficacy and safety of FA-AIT. Given that FA-AIT is time-consuming and burdened by potential side effects, patients and their families must be extremely adherent, reliable and committed to a treatment regimen that may cover a long period of time. Given these premises, poor adherence to the treatment is an absolute contraindication (Box 8). A clear and detailed explanation about the FA-AIT procedure (i.e. up-dosing schedules, setting), the related outcomes and risk of side effects, together with getting information on patients' and/or families' opinions and expectations are pre-requisites to the inclusion in the treatment protocol. Patients and their families need to be supported during the entire treatment. Informed consent should be signed by patients (where appropriate) and their parents.

SUMMARY, GAPS IN THE EVIDENCE AND FUTURE PERSPECTIVES
FA-AIT represents the active treatment of IgE-mediated FA instead of avoidance and rescue drug management. The usual management of FA demands changes in eating habits with serious repercussions on QoL, potential risk of nutritional deficiencies, especially in young children, and severe adverse reaction in case of accidental exposure to the culprit food.

The recent SR and meta-analysis on FA-AIT (18) clearly demonstrated that FA-AIT is effective in reducing the likelihood of reacting to foods while receiving the therapy. In pediatric patients with FA to CM and peanut, data suggest that OIT is more effective than SLIT (45, 55). There is an increased risk of local (the most frequent) reactions with both OIT and SLIT but only OIT showed a significantly higher risk of systemic reactions. Due to the length of the protocol and safety issues, patients and their families must be extremely adherent, reliable and committed to the treatment. FA-AIT may improve QoL scores, particularly with regard to social limitations, accidental exposure and anxiety, although further studies are needed (5).

Many children with CM allergy or HE allergy develop tolerance spontaneously. For this reason, for many patients and families, allergen avoidance whilst awaiting spontaneous resolution may represent a better option than FA-AIT. Therefore, FA-AIT cannot be recommended as routine practice, but must be limited only to carefully selected patients managed in specialized clinical settings, by trained personnel (Boxes 9 & 10).

There are still many gaps that need to be addressed (Table 7). The duration of FA-AIT may be burdensome for patients and their families. After completion of therapy, patients frequently need to continue to consume the allergen to maintain tolerance. It may be easier to achieve post-discontinuation effectiveness (e.g. tolerance or sustained unresponsiveness) for allergens that are typically outgrown in childhood (e.g. CM and HE) compared to other allergens (such as peanut), where probably lifelong ingestion may be required after therapy. In addition, efficacy during the treatment with CM can be maintained with a twice-weekly regimen. We await maintenance follow-up studies to assess whether more flexible regimens are possible with other foods (69).

The quality of allergen preparations is critical for both diagnosis and treatment. Standardized allergen preparations of known potency and shelf-life should be used. Currently, the allergens containing food protein and those prepared by pharmaceutical companies or hospital pharmacies are not available as standardized products. The allergens in such products should be well characterized as it is known that different formulations of a product may have significant variations in allergen load. Both the bacteriological load and biological activity of these products are still undetermined. Therefore, the use of fresh material or native foods for FA-AIT is advisable to achieve the goal of desensitization. Different disciplinary and clinical backgrounds including medical care, patient groups, allergen manufacturers and regulators should be involved in the process of producing new data on standardized allergen preparations for the active treatment of FA.
Novel therapeutic approaches are being developed to improve FA-AIT, most of them in pre-clinical or early clinical trials. In particular, co-administration of humanized monoclonal anti-IgE (omalizumab) seems to markedly reduce adverse reactions due to OIT compared to placebo (70-72). Furthermore, as bacteria are potent stimulants of Th1 immune responses, modified bacterial products are under investigation as adjuvants for FA-AIT (46). Clinical studies carried out with FA-AIT have some limitations, a key one is the heterogeneity in protocols between centers. It is yet unclear which duration and frequency of ingestion of the allergic food(s) is required to maintain desensitization. Furthermore,
we are lacking criteria with which to evaluate and diagnose permanent tolerance. In AIT trials and in clinical practice, safety is of the paramount importance: strategies for improving safety during either up-dosing protocol or maintenance regimen need to be standardized. Managing these pivotal issues is mandatory for use of OIT/SLIT outside research settings or specialized clinical centers for FA-AIT.

FA-AIT should be utilized for patients with persistent food allergy (Box 11). In many patients, the downside of the adverse events associated with treatment is outweighed by both the achievement of desensitization and the reduced risk of a serious allergic reaction by accidental exposure at home or in the community. Considering the current evidence, there are still considerable knowledge gaps about how best to perform FA-AIT and more well-designed AIT trials are required.

**Acknowledgements**

The EAACI Guideline: AIT for IgE-mediated food allergy Taskforce would like to thank Stefan Vieths and Andreas Bonertz for their advice; Sami L. Bahna, Paolo Meglio, Anna Nowak-Wegrzyn, and Hugh Sampson for their expert review of the draft guidelines; all the EAACI members who commented about the draft guideline on the public website; and EAACI and the BM4SIT project (grant number 601763) in the European Union’s Seventh Framework Programme FP7 for funding this guideline.

**Contributorship**

GB Pajno and M. Fernandez-Rivas jointly chaired the EAACI Guideline: AIT for IgE-mediated Food Allergy Taskforce. S Arasi, C Akdis, M Alvaro-Lozano, K Beyer, C Bindslev-Jensen, W Burks, M Ebisawa, P Eigenmann, EF Knol, KC Nadeau, A Muraro, LK Poulsen, R van Ree, G Roberts, A Santos, G du Toit, were members of the Taskforce involved in conceptualizing the guidelines, writing and critical revision of drafts. S Arasi, S Dhami, U Nurmatov and A Sheikh provided methodological support to the Taskforce. Y Boloh was the patients’ group representative. I Agache, E Angier, S Halken, M Jutel, S Lau, O Pfaar, R van Ree, D Ryan, G Sturm, E-M Varga, R Gerth van Wijk were members of the EAACI Guidelines Steering Committee and contributed in conceptualizing the guidelines and critically reviewed draft versions. All the authors satisfied the international authorship criteria with further details in the online supplement. This guideline is part of the EAACI Guidelines on Allergen Immunotherapy, chaired by A Muraro and coordinated by G Roberts.
References


